A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC (NCT06627647)
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.
Who can join: Review the eligibility criteria below.
Location: Research Site — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (295 Sites)
Showing the first 25 of 295 sites.
- Research Site — Mobile, Alabama
- Research Site — Chandler, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Anaheim, California
- Research Site — Beverly Hills, California
- Research Site — Loma Linda, California
- Research Site — Redlands, California
- Research Site — San Diego, California
- Research Site — San Francisco, California
- Research Site — Santa Rosa, California
- Research Site — Walnut Creek, California
- Research Site — Lone Tree, Colorado
- Research Site — Stamford, Connecticut
- Research Site — West Haven, Connecticut
- Research Site — Newark, Delaware
- Research Site — Bay Pines, Florida
- Research Site — Fort Lauderdale, Florida
- Research Site — Gainesville, Florida
- Research Site — Jacksonville, Florida
- Research Site — Miami, Florida
- Research Site — Ocala, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Atlanta, Georgia
- Research Site — Boise, Idaho
- Research Site — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-squamous Non-small Cell Lung Cancer
- Phase III Study of AK112 for NSCLC Patients — Bakersfield, California
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer — Chandler, Arizona
Explore by condition: All Non-squamous Non-small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.